Department of Orthopaedic Surgery, Mayo Clinic Arizona, Phoenix, Arizona.
Alix School of Medicine, Mayo Clinic, Scottsdale, Arizona.
J Arthroplasty. 2024 Aug;39(8):2003-2006.e1. doi: 10.1016/j.arth.2024.02.067. Epub 2024 Feb 28.
Rheumatoid arthritis (RA) has historically been considered a contraindication for unicompartmental knee arthroplasty (UKA). However, the widespread use of disease-modifying antirheumatic drugs has substantially improved the management of RA and prevented disease progression. The objective of this study was to ascertain whether RA impacts UKA revision-free survivorship.
Patients undergoing UKA from 2010 to 2021 were identified in an administrative claims database (n = 105,937) using Current Procedural Terminology code 27446. All patients who underwent UKA who had a diagnosis of RA with a minimum of 2-year follow-up (n = 1,422) were propensity score matched based on age, sex, and Elixhauser Comorbidity Index to those who did not have RA (n = 1,422). Laterality was identified using the 10th Revision of International Classification of Diseases codes. The primary outcome was ipsilateral revision to total knee arthroplasty (TKA) within 2 years, and the secondary outcome was ipsilateral revision at any time.
Among the 1,422 patients who had a UKA and a diagnosis of RA, 37 patients (2.6%) underwent conversion to TKA within 2 years, and 48 patients (3.4%) underwent conversion to TKA at any point. In comparison, 28 patients (2.0%) in the propensity-matched control group underwent conversion to TKA within 2 years, and 40 patients (2.8%) underwent conversion to TKA at any point. Statistical analysis revealed no significant difference in conversion to TKA between patients who had and did not have RA, either within 2 years (P = .31) or anytime (P = .45).
Patients who had RA and underwent UKA did not have an increased risk of revision to TKA compared to those who did not have RA. This may indicate that modern management of RA could allow for expanded UKA indications for RA patients.
类风湿关节炎(RA)在过去被认为是膝关节单髁置换术(UKA)的禁忌症。然而,疾病修饰抗风湿药物的广泛应用极大地改善了 RA 的治疗效果,防止了疾病进展。本研究旨在确定 RA 是否影响 UKA 无翻修生存率。
使用当前程序术语代码 27446 在行政索赔数据库中确定 2010 年至 2021 年接受 UKA 的患者(n=105937)。所有接受 UKA 且至少有 2 年随访时间并诊断为 RA 的患者(n=1422)根据年龄、性别和 Elixhauser 合并症指数与未患有 RA 的患者(n=1422)进行倾向评分匹配。使用国际疾病分类第 10 版代码确定侧别。主要结果是 2 年内同侧行全膝关节置换术(TKA)翻修,次要结果是任何时间同侧翻修。
在 1422 例接受 UKA 且诊断为 RA 的患者中,37 例(2.6%)在 2 年内行 TKA 翻修,48 例(3.4%)在任何时间行 TKA 翻修。相比之下,在倾向评分匹配的对照组中,28 例(2.0%)在 2 年内行 TKA 翻修,40 例(2.8%)在任何时间行 TKA 翻修。统计学分析显示,无论在 2 年内(P=0.31)还是任何时间(P=0.45),RA 患者与未患有 RA 的患者行 TKA 翻修无显著差异。
与未患有 RA 的患者相比,患有 RA 且接受 UKA 的患者行 TKA 翻修的风险并未增加。这可能表明现代 RA 治疗方法可以为 RA 患者扩大 UKA 适应证。